[AGTC] Applied Genetic Technologies Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 9.95 Change: 0.45 (4.74%)
Ext. hours: Change: 0 (0%)

chart AGTC

Refresh chart

Description: Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company?s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma. The company was founded in 1999 and is headquartered in Alachua, Florida.

Fundamental Ratios
Shares Outstanding EPS0.41 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 129.03% Sales Growth - Q/Q-56.44% P/E12.32
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.62% ROE-22.5% ROI
Current Ratio17.17 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin-1185.67% Net Profit Margin-1182.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities32.16 M Cash From Investing Activities16.78 M Cash From Operating Activities-13.08 M Gross Profit
Net Profit-6.33 M Operating Profit-6.39 M Total Assets96.58 M Total Current Assets65.11 M
Total Current Liabilities3.79 M Total Debt Total Liabilities3.79 M Total Revenue280 K
Technical Data
High 52 week10.05 Low 52 week3.4 Last close4.2 Last change-2.33%
RSI67.86 Average true range0.21 Beta1.51 Volume53.6 K
Simple moving average 20 days8.53% Simple moving average 50 days10.66% Simple moving average 200 days-9.89%
Performance Data
Performance Week-2.33% Performance Month16.67% Performance Quart7.69% Performance Half-14.29%
Performance Year-54.59% Performance Year-to-date16.67% Volatility daily2.87% Volatility weekly6.41%
Volatility monthly13.14% Volatility yearly45.51% Relative Volume237.74% Average Volume104.71 K
New High New Low

News

2020-05-26 10:50:02 | Why Applied Genetic Technologies AGTC Stock Might be a Great Pick

2020-05-25 12:00:04 | Applied Genetic Technologies AGTC Upgraded to Strong Buy: Here's What You Should Know

2020-05-25 11:30:03 | Is Applied Genetic Technologies AGTC Outperforming Other Medical Stocks This Year?

2020-05-20 07:00:10 | AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa XLRP

2020-05-15 06:24:59 | Is Applied Genetic Technologies NASDAQ:AGTC In A Good Position To Invest In Growth?

2020-05-14 00:49:17 | Edited Transcript of AGTC earnings conference call or presentation 13-May-20 12:00pm GMT

2020-05-13 10:45:02 | Applied Genetic Technologies AGTC Reports Q3 Loss, Misses Revenue Estimates

2020-05-13 08:25:12 | Applied Genetic Technologies' Shares March Higher, Can It Continue?

2020-05-13 07:00:10 | AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020

2020-05-12 08:00:10 | Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program

2020-05-06 07:00:10 | AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020

2020-04-28 12:34:04 | Earnings Preview: Applied Genetic Technologies AGTC Q3 Earnings Expected to Decline

2020-04-22 07:20:11 | Applied Genetic Technologies' Shares March Higher, Can It Continue?

2020-03-24 12:00:04 | All You Need to Know About Applied Genetic Technologies AGTC Rating Upgrade to Buy

2020-03-16 07:00:10 | AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia

2020-02-19 07:00:10 | AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

2020-02-16 08:50:08 | 2 “Strong Buy” Healthcare Stocks with Over 100% Upside Potential

2020-02-06 20:06:24 | AGTC Announces Pricing of $32,500,000 Public Offering of Common Stock

2020-02-06 07:47:50 | The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

2020-02-05 16:36:58 | AGTC Announces Proposed Public Offering of Common Stock

2020-01-28 07:30:10 | Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program

2020-01-23 07:00:10 | AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia

2020-01-22 16:01:10 | AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

2020-01-21 07:00:10 | AGTC Announces Agenda for R&D Day on January 28, 2020 in New York

2020-01-10 10:08:03 | Applied Genetic Stock Up on Favorable Eye Therapy Study Data

2020-01-10 09:08:02 | Company News for Jan 10, 2020

2020-01-10 09:07:02 | Implied Volatility Surging for Applied Genetic Technologies AGTC Stock Options

2020-01-10 07:13:12 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

2020-01-10 04:58:57 | The Applied Genetic Technologies NASDAQ:AGTC Share Price Has Gained 190%, So Why Not Pay It Some Attention?

2020-01-09 10:02:47 | Applied Genetic Shares Rip Higher After Eye Disorder Gene Therapy Aces Midstage Trial

2020-01-09 08:39:54 | The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

2020-01-09 08:34:00 | Applied Genetic Technologies' stock rockets on early-stage eye therapy data

2020-01-09 07:00:10 | AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa

2020-01-08 16:01:10 | AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Trial

2019-12-19 09:17:00 | Biotech Stocks Are In a Position to Break Out in 2020, Analysts Say

2019-12-17 19:36:43 | Is Applied Genetic Technologies Corp AGTC A Good Stock To Buy?

2019-12-03 07:59:26 | The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

2019-12-02 16:35:10 | AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020

2019-11-13 12:34:48 | Edited Transcript of AGTC earnings conference call or presentation 12-Nov-19 9:30pm GMT

2019-11-12 17:55:10 | Applied Genetic Technologies AGTC Reports Q1 Loss, Lags Revenue Estimates

2019-11-12 16:01:00 | AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019

2019-11-06 07:00:00 | AGTC to Host First Quarter Results Conference Call and Webcast on November 12, 2019

2019-11-05 07:00:00 | AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program and Reports Compelling Preclinical Data Supporting the Potential of its Dual-Vector Technology

2019-10-31 06:38:19 | We Think Applied Genetic Technologies NASDAQ:AGTC Can Afford To Drive Business Growth

2019-10-21 07:00:05 | AGTC Presents Data Demonstrating Efficiency of its AAV Vectors for Ocular Gene Therapy Even in the Presence of Anti-AAV Antibodies

2019-10-01 07:30:00 | AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

2019-09-30 12:03:32 | Applied Genetic Notches Sell-Side Upgrade After Releasing Interim Study Data

2019-09-27 19:59:26 | Edited Transcript of AGTC earnings conference call or presentation 26-Sep-19 8:30pm GMT

2019-09-26 17:35:09 | Applied Genetic Technologies AGTC Reports Q4 Loss, Lags Revenue Estimates

2019-09-26 16:01:00 | AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019